Liver cancer has been escalated to be the 2nd cause of cancer-related death worldwide. Many of the classical onocgenic pathways have been shown to play critical roles in human liver tumorigenesis, and therefore become drug targets in therapy. Unfortunately, these mechanism-based approaches have achieved very little or at most temporary effect in the clinical treatment. Consistent to this disappointing outcome in therapeutics, we and others have uncovered anti-oncogenic roles for many pro-oncogenic molecules in the liver. We believe that these apparently “conflicting” data do not necessarily obscure the mechanisms underlying hepatocarcinogenesis. In contrast, elucidating the “paradoxical” roles of these molecules will lead to a paradigm shift in liver cancer, and may provide novel diagnostic and therapeutic strategies for this malignant disease.
2021.12.07 A New Strategy to Transform Liver Cancer Immunotherapy
For most liver cancer patients, immunotherapy does not produce effective results but new data suggests a revamped strategy can make unresponsive liver tumors highly responsive. Read More
2021.11.09 A Target for Potential Cancer Drugs May, In Fact, Worsen Disease
Inhibiting the enzyme Shp2 in tumor cells theoretically stops disease progression, but new data suggests it may actually boost tumor growth. Read More
2019.12.16 Math Equation Predicts and Detects Liver Cancer
UC San Diego researchers pinpoint moment when healthy liver cells become cancerous. Read More
2017.11.14 A New Strategy for Prevention of Liver Cancer Development
A synthetic double-stranded RNA has potential for use as an anti-liver cancer vaccine. Read More
1. JJ Liu, B Xin, L Du, L Chen, Y Long, and GS Feng. Pharmaceutical SH2 domain–containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity. Hepatology 2022, Accession number: 35503714 DOI: 10.1002/hep.32555, https://pubmed.ncbi.nlm.nih.gov/35503714
2. KL Hanley, X Lin, Y Liang, M Yang, M Karin, W Fu, and GS Feng. Concurrent Disruption of Ras/MAPK and NF-kB Pathways Induces Circadian Dysregulation and Hepatocarcinogenesis. Molecular Cancer Research 2022, Accession number: 34810213 DOI: 10.1158/1541-7786.MCR-21-0479, https://pubmed.ncbi.nlm.nih.gov/34810213
3. Y Liang, K Kaneko, B Xin, J Lee, X Sun, K Zhang, and GS Feng. Temporal analysis of postnatal liver development and maturation by single cell transcriptomics. Developmental Cell 2022, Accession number: 35134346 DOI: 10.1016/j.devcel.2022.01.004, https://pubmed.ncbi.nlm.nih.gov/35134346
4. B Xin, M Yang, P Wu, L Du, HX Deng, E Hui, and GS Feng. Enhancing the therapeutic efficacy of PD-L1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance. Hepatology 2021, Accession Number: 34860431 DOI: 10.1002/hep.32266, https://www.ncbi.nlm.nih.gov/pubmed/34860431
5. WS Chen, Y Liang, M Zong, JJ Liu, K Kaneko, KL Hanley, K Zhang, and GS Feng. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment. Cell Reports, 2021 Vol. 37 Issue 6 Pages 109974, Accession Number: 34758313 DOI: 10.1016/j.celrep.2021.109974, https://www.ncbi.nlm.nih.gov/pubmed/34758313
Congrats to Our Postdocs and Grads!
Jacey Liu: Successful PhD Dissertation Defense Apr. 21 2022 !!
Wendy Chen: Successful PhD Dissertation Defense Oct. 7th 2021!!
Yan Liang: Successful PhD Dissertation Defense Aug. 23rd 2021!!!
Jin Lee: 3-Year Pinnacle Research Award from American Association for the Study of Liver Diseases 2021!!!
Kaisa Hanley: Successful PhD Dissertation Defense Dec.9th 2020!!
Jacey Liu: David V. Goeddel Chancellor's Graduate Fellowship 2019!
Wendy Chen: Biochem of Growth Reg. and Oncogenesis Training NIH Grant 2018!
Kota Kaneko: Cancer Biology Post-Doctoral Fellowship 2016!